Published: 1 November 2021
Author(s): Miguel Marques Antunes, Mariana Alves, Fausto J. Pinto, Giancarlo Agnelli, Daniel Caldeira
Issue: January 2022
Section: Original Article

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is a potentially life-threatening condition associated with a high case-fatality rate [1], and holds a high risk of recurrence reaching a cumulative 10-year rate of 30% [2]. In order to treat VTE and prevent recurrences, anticoagulant treatment is required for a period of at least three months in any VTE setting. Treatment can be discontinued thereafter if there is a major transient/reversible risk factor related to the onset of VTE.


Stay informed on our latest news!


This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.